Nuvation Bio Inc
NUVBHealthcare|Biotechnology|USA
$5.81
-0.30 (-4.91%)
Tangible Book
$0.89
Clinical Trials (18)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05303519 SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Glioma, Astrocytoma, Grade IV | P3 | Recruiting | 365 | RCT, Double-blind | safusidenib, Placebo |
| NCT06564324 A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | Non Small Cell Lung Cancer | P3 | Recruiting | 194 | RCT, Open-label | Taletrectinib, Crizotinib |
| NCT07154706 Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | Non-small Cell Lung Cancer (NSCLC) | P3 | Recruiting | 180 | RCT, Double-blind | Taletrectinib, Placebo |
| NCT04395677 A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | Non Small Cell Lung Cancer | P2 | Active | 173 | Open-label | AB-106 |
| NCT04919811 Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | Non Small Cell Lung Cancer | P2 | Active | 217 | Open-label | Taletrectinib |
| NCT06334432 Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Advanced Solid Tumor, HER2-negative Breast Cancer | P1P2 | Active | 466 | Open-label | NUV-1511 |
| NCT04151342 CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) | Cancer, Malignancies Multiple | Recruiting | 5,500 | — | Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents. | |
| NCT05191017 Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | Prostate Cancer, Prostatic Cancer | P1P2 | Withdrawn | — | Open-label | NUV-422, Enzalutamide |
| NCT04617054 Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion | Solid Tumor | P2 | Terminated | 14 | Open-label | AB-106 |
| NCT05191004 Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Advanced Breast Cancer, Metastatic Breast Cancer | P1P2 | Withdrawn | — | RCT, Open-label | NUV-422, Fulvestrant |
| NCT05357820 A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK | Solid Tumor | P1 | Completed | 56 | Open-label | AB-106, Itraconazole, AB-106, Rifampicin |
| NCT02279433 A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Solid Tumors | P1 | Completed | 46 | Open-label | DS6051b |
| NCT04541225 Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | Glioma, Glioma, Malignant | P1 | Terminated | 74 | Open-label | NUV-422 |
| NCT05357911 A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin | Solid Tumor | P1 | Completed | 16 | Open-label | AB-106, digoxin |
| NCT05252390 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | Advanced Solid Tumor, Ovarian Cancer | P1 | Terminated | 82 | Open-label | NUV-868, Olaparib, Enzalutamide |
| NCT05609929 Study the Effect of Omeprazole on AB-106 Pharmacokinetics | Pharmacokinetic Study | P1 | Completed | 24 | Open-label | Multiple administration of omeprazole Single administration of AB-106 |
| NCT05577416 A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma | Glioma | Early P1 | Completed | 14 | Open-label | Part A: Safusidenib Erbumine, Part B: Safusidenib Erbumine |
| NCT06841874 Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC | Lung Neoplasms, Respiratory Tract Neoplasms | NO_LONGER_AVAILABLE | — | — | Taletrectinib |